 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.  
         Underlining  indicates amendments to bill.  
         Strike out  indicates matter stricken from the bill by amendment or deleted from the law by 
amendment.             *hb1502*      
HOUSE BILL 1502  
J1   5lr3585  
    CF 5lr3586  
By: Delegate Wells (By Request – Baltimore City Administration)  
Introduced and read first time: February 14, 2025  
Assigned to: Rules and Executive Nominations  
Re–referred to: Health and Government Operations, February 25, 2025  
Committee Report: Favorable  
House action: Adopted  
Read second time: March 6, 2025  
 
CHAPTER ______  
 
AN ACT concerning  1 
 
Baltimore City – AIDS  Prevention Sterile Needle and Syringe  Exchange Pilot  2 
Program  – Revisions  3 
 
FOR the purpose of renaming the AIDS Prevention Sterile Needle and Syringe Exchange 4 
Pilot Program to be the HIV Prevention Syringe Services Program; altering the 5 
duties of the Program, the Director of the Program , and the Baltimore City Health 6 
Department  regarding the Program; altering the membership  and duties  of the 7 
Program’s oversight committee; altering the immunity provided to Program staff and 8 
participants;  and genera lly relating to the AIDS Prevention Sterile Needle and 9 
Syringe Exchange Pilot Program . 10 
 
BY repealing and reenacting, without amendments,  11 
 Article – Health – General  12 
Section 24 –801(a)  13 
 Annotated Code of Maryland  14 
 (2023 Replacement Volume and 2024 Suppleme nt) 15 
 
BY repealing and reenacting, with amendments,  16 
 Article – Health – General  17 
Section 24 –801(e), 24 –802 through 24 –806, 24–808, and 24–809 18 
 Annotated Code of Maryland  19 
 (2023 Replacement Volume and 2024 Supplement)  20 
 
2 HOUSE BILL 1502   
 
  SECTION 1. BE IT ENACTED BY THE GENERAL  ASSEMBLY OF MARYLAND, 1 
That the Laws of Maryland read as follows:  2 
 
Article – Health – General  3 
 
24–801. 4 
 
 (a) In this subtitle the following words have the meanings indicated.  5 
 
 (e) “Program” means the [AIDS ] HIV  Prevention [Sterile Needle and ] Syringe 6 
[Exchange Pilot ] SERVICES  Program.  7 
 
24–802. 8 
 
 (a) There is an [AIDS ] HIV  Prevention [Sterile Needle and ] Syringe [Exchange 9 
Pilot] SERVICES  Program in the Baltimore City Health Department.  10 
 
 (b) The Program shall:  11 
 
  (1) [Provide ] DISTRIBUTE SYRINGES A ND PRO VIDE for the exchange by 12 
participants of used hypodermic needles and syringes for sterile hypodermic needles and 13 
syringes  AS NEEDED ; and  14 
 
  (2) Operate in accordance with the procedures approved, with the advice 15 
and approval of the oversight committee, by the Commissioner of Health.  16 
 
24–803. 17 
 
 The Program shall:  18 
 
  (1) Be designed and maintained to provide [maximum security of exchange 19 
locations and equipment, including ] security measures [that may be ] AND PROCESSES 20 
required to [control the use and dispersa l of] SAFELY DISTRIBUTE hypodermic needles 21 
and syringes and [security measures that allow for a full accounting of ] ACCOUNT FOR  the 22 
number of hypodermic needles and syringes [in circulation ] EXCHANGED AND 23 
DISTRIBUTED BY THE BALTIMORE CITY HEALTH DEPARTMENT  and the number of 24 
hypodermic needles and syringes in storage;  25 
 
  (2) Be operated to allow participants to exchange used hypodermic needles 26 
and syringes at [any exchange location, if more than one location is ] available  MOBILE 27 
SYRINGE SERVICES SIT ES; 28 
 
  (3) Include appropriate levels of staff expertise in working with injecting 29 
drug users and adequate staff training in providing community SERVICE PROVIDER 30 
referrals, counseling, and preventive education;  31 
 
 HOUSE BILL 1502  3 
 
   (4) Provide for the dissemination of other preventive means for [curtailing 1 
the spread of the HIV infection ] DECREASING THE RISK OF HIV  TRANSMISSION ; 2 
 
  (5) Provide [a linkage for ] referrals to drug counseling and treatment 3 
services, and follow –up to those ref errals to assure that participants receive the treatment 4 
they desire;  5 
 
  (6) Educate injecting drug users on the [dangers of contracting the HIV 6 
infection ] RISK OF TRANSMITTING  HIV  or the hepatitis B virus through HIGH–RISK 7 
needle –sharing practices and [unsafe] sexual behaviors;  8 
 
  (7) Include policies and procedures for the screening of applicants to the 9 
Program in order to preclude noninjecting drug users from participating in the Program;  10 
AND 11 
 
  (8) [Establish ] IMPLEMENT  procedures for identifying Progra m 12 
participants that are consistent with the confidentiality provisions of this subtitle [; and 13 
 
  (9) Establish a method of identification and authorization for Program staff 14 
members who have access to hypodermic needles, syringes, or Program records ]. 15 
 
24–804. 16 
 
 (a) The Mayor of Baltimore City shall appoint an oversight committee for the 17 
Program.  18 
 
 (b) The oversight committee shall consist of:  19 
 
  (1) [Two representatives ] ONE REPRESENTATIVE  from academia who 20 
[specialize ] SPECIALIZES  in public health issu es; 21 
 
  (2) One representative from law enforcement [, nominated by the Secretary 22 
of Public Safety and Correctional Services ]; 23 
 
  [(3) One representative of the Baltimore City Police Department; ] 24 
 
  [(4)] (3) [Two representatives ] ONE REPRESENTATIVE  from the  25 
Maryland Department of Health [, the Department of Juvenile Services, or the Department 26 
of Education, nominated by the Secretary of Health ]; 27 
 
  [(5)] (4) One representative of a Baltimore City community group;  28 
 
  [(6)] (5) One representative of an [AIDS ] HIV  advocacy group;  29 
 
  [(7)] (6) One [drug abuse ] ADDICTION  treatment counselor;  30 
4 HOUSE BILL 1502   
 
  
  [(8)] (7) One recovering injecting drug user; and  1 
 
  [(9)] (8) Up to three other individuals whom the [Mayor of Baltimore 2 
City] BALTIMORE CITY HEALTH DEPARTMENT  determines to be appropriate for 3 
appointment to the oversight committee.  4 
 
 (c) The oversight committee shall:  5 
 
  (1) Provide advice to the Commissioner of Health and the Program Director 6 
on developing  AND REVISING AS NECE SSARY : 7 
 
   (i) Program operating procedures fo r the [furnishing ] 8 
DISTRIBUTION  and exchange of hypodermic needles and syringes to injecting drug users;  9 
 
   (ii) A plan for community outreach and education;  10 
 
   (iii) A protocol for providing [a linkage ] REFERRALS  for Program 11 
participants to [substance abuse ] ADDICTION  treatment and rehabilitation; and  12 
 
   (iv) A plan for evaluating the Program; and  13 
 
  (2) Provide ongoing oversight of the Program and make recommendations 14 
to the Program Director or the Commissioner of Health regarding any aspect of Progra m 15 
procedures, operation, or evaluation.  16 
 
24–805. 17 
 
 (a) The Commissioner of Health shall appoint a Director for the Program.  18 
 
 (b) With the advice [and approval ] of the oversight committee, the Director shall 19 
develop  AND REVISE AS NECESS ARY: 20 
 
  (1) Program operating procedures for the [furnishing ] DISTRIBUTION  and 21 
exchange of hypodermic needles and syringes to injecting drug users;  22 
 
  (2) A community outreach and education program; and  23 
 
  (3) A protocol for providing [a linkage ] REFERRALS  for Program  24 
participants to substance abuse treatment and rehabilitation.  25 
 
 (c) The Director shall submit the operating procedures, the plan for a community 26 
outreach and education program, and the [substance abuse ] ADDICTION  treatment 27 
[linkage ] REFERRAL  protocol to the Commissioner of Health  OR THE COMMISSIONER ’S 28 
DESIGNEE  for approval prior to THE implementation  OF REVISED PROCEDURES . 29 
 
 HOUSE BILL 1502  5 
 
 24–806. 1 
 
 (a) The Baltimore City Health Department shall include in its Program operating 2 
procedures measures to collect  the following data:  3 
 
  (1) The number of participants served by the Program;  4 
 
  (2) The length of time a participant is served by the Program;  5 
 
  (3) Demographic profiles of participants served by the Program that 6 
include:  7 
 
   (i) Age; 8 
 
   (ii) Sex; 9 
 
   (iii) Race;  AND 10 
 
   [(iv) Occupation; ] 11 
 
   [(v)] (IV) Zip code of residence;  12 
 
   [(vi) Types of drugs used;  13 
 
   (vii) Length of drug use; and  14 
 
   (viii)  Frequency of injection; ] 15 
 
  (4) The number of hypodermic needles and syringes exchanged;  16 
 
  (5) The number of participants [entering  drug counseling and ] REFERRED 17 
TO ADDICTION  treatment; and  18 
 
  (6) The number of referrals made by the Program for [drug counseling and ] 19 
ADDICTION  treatment  FOR PEOPLE WHO INJEC T DRUGS . 20 
 
 (b) With the advice [and approval ] of the oversight committee, the Baltimore City 21 
Health Department shall develop and implement a plan for Program evaluation that shall 22 
include the following issues:  23 
 
  (1) The ESTIMATED prevalence  AND INCIDENCE  of HIV among Program 24 
participants;  25 
 
  [(2) Changes in the level of drug use among Program participants;  26 
 
  (3) Changes in the level of needle –sharing among Program participants;  27 
6 HOUSE BILL 1502   
 
  
  (4) Changes in the use of condoms among Program participants;  1 
 
  (5) The status of treatment and recovery for Program participants who 2 
entered drug treatment programs;  3 
 
  (6) The impact of the Program on risk behaviors for the transmission of the 4 
HIV infection, the hepatitis B virus, and other life –threatening blood –borne diseases 5 
among injecting drug users;  6 
 
  (7) The co st–effectiveness of the Program versus the direct and indirect 7 
costs of the HIV infection in terms of medical treatment and other services normally 8 
required by HIV –infected individuals; ] 9 
 
  [(8)] (2) The strengths and weaknesses of the Program; and  10 
 
  [(9)] (3) The advisability of continuing the Program.  11 
 
 (c) As part of its plans for data collection and Program evaluation described under 12 
subsections (a) and (b) of this section, the Baltimore City Health Department shall develop 13 
and implement a methodology [: 14 
 
  (1) For identifying Program hypodermic needles and syringes, such as 15 
through the use of bar coding or any other method approved by the oversight committee; 16 
and 17 
 
  (2) To perform HIV antibody testing on the residue left in a sample of 18 
hypodermic needle s and syringes returned to the Program ] TO COLLECT RETURNED 19 
NEEDLES AND SYRINGES  AND SEND THEM TO THE  RAPID ANALYSIS OF DRUGS 20 
PROGRAM OPERATED BY T HE CENTER FOR HARM REDUCTION AT THE MARYLAND 21 
DEPARTMENT OF HEALTH . 22 
 
 (d) On or before December 31 of each yea r, the Baltimore City Health Department 23 
shall report to the oversight committee, the Governor, and, in accordance with § 2 –1257 of 24 
the State Government Article, the General Assembly, on the number of hypodermic needles 25 
and syringes exchanged as part of the  Program.  26 
 
24–808. 27 
 
 [(a)] No Program staff member or Program participant may be found guilty of 28 
violating § 5 –601, § 5 –619, § 5 –620, § 5 –902, or § 5 –904 of the Criminal Law Article for 29 
possessing or distributing controlled paraphernalia or drug parapherna lia whenever the 30 
possession or distribution of the controlled paraphernalia or drug paraphernalia is a direct 31 
result of the employee’s or participant’s activities in connection with the work of the 32 
Program authorized under this subtitle.  33 
 
 HOUSE BILL 1502  7 
 
  [(b) Notwithstan ding the provisions of subsection (a) of this section, a Program 1 
staff member or Program participant is not immune from criminal prosecution for:  2 
 
  (1) The redistribution of hypodermic needles or syringes in any form;  3 
 
  (2) Any activities not authorized or approved by the Program; or  4 
 
  (3) The possession or distribution of controlled paraphernalia or drug 5 
paraphernalia or any other unlawful activity outside of the Baltimore City limits. ] 6 
 
24–809. 7 
 
 Except for violations of any laws that could arise from residue attached to or 8 
contained within hypodermic needles or syringes being returned or already returned to the 9 
Program, [nothing in ] this subtitle [provides ] DOES NOT PROVIDE  immunity to a Program 10 
staff member or Program participant from criminal prosecution for a violation of any law 11 
prohibiting or regulating the use, possession, dispensing, distribution, or promotion of 12 
[controlled dangerous substances, dangerous drugs, detr imental drugs, or harmful drugs 13 
or any conspiracy or attempt to commit any of those offenses ] ILLICIT DRUGS . 14 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 15 
October 1, 2025.  16 
 
 
 
Approved:  
________________________________ ________________________________ ________________   
           Governor.  
________________________________ ________________________________ ________________   
         Speaker of the House of Delegates.  
________________________________ ________________________________ ________________   
                 President of the Senate.  